Stoffwechselerkrankungen

Entsprechend ihrer Wanderung bei isoelektrischer Fokussierung werden die allelen Varianten des α1-AT als Proteinaseinhibitorphänotypen (Pi) klassifiziert. Die dominierende Isoform ist der normale Phänotyp M, daneben gibt es die Mangelvarianten S und Z sowie eine 0-Variante.

• Publication year

  2013

• Venue

  Pädiatrische Gastroenterologie, Hepatologie und Ernährung

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1007/978-3-642-24710-1_17PMCID 7498805
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Regulation of the release of alveolar macrophage-derived neutrophil chemotactic factor.

  2015cited by this paper
• Diagnosis of Nonalcoholic Fatty Liver Disease in Children and Adolescents: Position Paper of the ESPGHAN Hepatology Committee

  2012cited by this paper
• Inborn Metabolic Diseases: Diagnosis and Treatment

  2012cited by this paper
• Inborn Metabolic Diseases Diagnosis and Treatment, 5th edn Jean‐Marie Saudubray, Georges Van den Berghe, Walter John H. (eds). Berlin‐Heidelberg: Springer, 2012, hardcover, 656 pp., Price: € 159.95, US$ 209.00, ISBN 978‐3‐642‐15719‐6.

  2012cited by this paper
• Cognitive, neurophysiological, neurological and psychosocial outcomes in early-treated PKU-patients: a start toward standardized outcome measurement across development.

  2011cited by this paper
• Functional outcome of children with mitochondrial diseases.

  2011cited by this paper
• CDG – an update

  2011cited by this paper
• Correction of Hyperbilirubinemia in Gunn Rats Using Clinically Relevant Low Doses of Helper-Dependent Adenoviral Vectors

  2011cited by this paper
• Lysosomal storage diseases as differential diagnosis of hepatosplenomegaly.

  2010cited by this paper
• Re‐evaluation of the diagnostic criteria for Wilson disease in children with mild liver disease

  2010cited by this paper
• Therapeutic efficacy of alpha-1 antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of 2 randomised clinical trials using computed tomography densitometry

  2010cited by this paper
• Novel mechanism of fetal hepatocyte injury in congenital alloimmune hepatitis involves the terminal complement cascade

  2010cited by this paper
• Current international perspectives on hematopoietic stem cell transplantation for inherited metabolic disorders.

  2010cited by this paper
• Lysosomal storage disease: revealing lysosomal function and physiology.

  2010cited by this paper
• Fatty acid oxidation disorders: outcome and long-term prognosis

  2010cited by this paper
• Gilbert's syndrome--does it exist? A study of the prevalence of symptoms in Gilbert's syndrome.

  2009cited by this paper
• Oral cholic acid for hereditary defects of primary bile acid synthesis: a safe and effective long-term therapy.

  2009cited by this paper
• Single nucleotide polymorphism–mediated translational suppression of endoplasmic reticulum mannosidase I modifies the onset of end‐stage liver disease in alpha1‐antitrypsin deficiency

  2009cited by this paper
• Management and outcome in 75 individuals with long-chain fatty acid oxidation defects: results from a workshop

  2009cited by this paper
• Lysosomal Storage Disorders in the Newborn

  2009cited by this paper
• Treatment of neonatal hemochromatosis with exchange transfusion and intravenous immunoglobulin.

  2009cited by this paper
• Liver cell transplantation for Crigler-Najjar syndrome type I: update and perspectives.

  2008cited by this paper
• Neutrophil stress and apoptosis underlie myeloid dysfunction in glycogen storage disease type Ib.

  2008cited by this paper
• Environmental and genetic modifiers of the progression to fibrosis and cirrhosis in hemochromatosis.

  2008cited by this paper
• Glycogen storage disease type I: indications for liver and/or kidney transplantation

  2007cited by this paper
• Glycogen storage disease type I: diagnosis and phenotype/genotype correlation

  2007cited by this paper
• Non-HFE haemochromatosis.

  2007cited by this paper
• A polymorphism of the alpha1‐antitrypsin gene represents a risk factor for liver disease

  2007cited by this paper
• Resolution of decompensated cirrhosis from Wilson's disease with zinc monotherapy: a potential therapeutic option?

  2006cited by this paper
• Assignment of the o1-Antitrypsin Gene and a Sequence-Related Gene to Human Chromosome 14 by Molecular Hybridization

  2006cited by this paper
• Neonatal Hemochromatosis: Long-term Experience With Favorable Outcome

  2006cited by this paper
• Bile Acid Synthetic Defects and Liver Disease: A Comprehensive Review

  2006cited by this paper
• Iron Imports. VI. HFE and regulation of intestinal iron absorption.

  2006cited by this paper
• The epidemiology of medium chain acyl-CoA dehydrogenase deficiency: An update

  2006cited by this paper
• MPV17 encodes an inner mitochondrial membrane protein and is mutated in infantile hepatic mitochondrial DNA depletion

  2006cited by this paper
• Successful treatment of UGT1A1 deficiency in a rat model of Crigler-Najjar disease by intravenous administration of a liver-specific lentiviral vector.

  2006cited by this paper
• Metalloporphyrins for the treatment of neonatal jaundice

  2005cited by this paper
• Recommendations for the Diagnosis and Treatment of the Acute Porphyrias

  2005cited by this paper
• Wilson's disease: clinical management and therapy.

  2005cited by this paper
• Hepatocellular carcinoma in glycogen storage disease type Ia: A case series

  2005cited by this paper
• Infantile hepatocerebral syndromes associated with mutations in the mitochondrial DNA polymerase-gammaA.

  2005cited by this paper
• Successful gene therapy of the Gunn rat by in vivo neonatal hepatic gene transfer using murine oncoretroviral vectors

  2005cited by this paper
• Neonatal hemochromatosis: is it an alloimmune disease?

  2005cited by this paper
• The spectrum of aldolase B (ALDOB) mutations and the prevalence of hereditary fructose intolerance in Central Europe

  2005cited by this paper
• Neonatal hemochromatosis — medical treatment vs. transplantation: The king's experience

  2005cited by this paper
• Current role of liver transplantation for the treatment of urea cycle disorders: A review of the worldwide English literature and 13 cases at Kyoto University

  2005cited by this paper
• New developments in urea cycle disorders. Proceedings of a satellite workshop at the IX International Congress on Inborn Errors of Metabolism. August 31-September 1, 2003. Sydney, Australia.

  2004cited by this paper
• Approaches to mitochondrial gene therapy.

  2004cited by this paper
• Enzyme replacement and enhancement therapies for lysosomal diseases

  2004cited by this paper
• Studies of Pediatric Liver Transplantation 2002: Patient and graft survival and rejection in pediatric recipients of a first liver transplant in the United States and Canada

  2004cited by this paper
• Treatment of lysosomal storage disorders: Cell therapy and gene therapy

  2004cited by this paper
• Simultaneous liver-kidney transplantation for glycogen storage disease type IA (von Gierke's disease).

  2004cited by this paper
• Genetic defects in fatty acid beta-oxidation and acyl-CoA dehydrogenases. Molecular pathogenesis and genotype-phenotype relationships.

  2004cited by this paper
• Allogeneic stem cell transplantation for the treatment of lysosomal and peroxisomal metabolic diseases

  2004cited by this paper
• Molecular adsorbent recirculating system for acute and acute‐on‐chronic liver failure: A meta‐analysis

  2004cited by this paper
• State-of-the-art 2003 on PKU gene therapy.

  2004cited by this paper
• Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis

  2003cited by this paper
• Obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease.

  2003cited by this paper
• Early diagnosis of inherited metabolic disorders towards improving outcome: the controversial issue of galactosaemia

  2003cited by this paper
• Insights into the diagnosis and treatment of lysosomal storage diseases.

  2003cited by this paper
• Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homoeostasis.

  2003cited by this paper
• Outcome and survival of 88 patients with urea cycle disorders: a retrospective evaluation

  2003cited by this paper
• Diagnosis and phenotypic classification of Wilson disease 1

  2003cited by this paper
• Liver disease caused by failure to racemize trihydroxycholestanoic acid: gene mutation and effect of bile acid therapy.

  2003cited by this paper
• Mitochondrial disorders: Clinical presentation and diagnostic dilemmas

  2003cited by this paper
• Mitochondrial disorders

  2003cited by this paper
• Use of tandem mass spectrometry for multianalyte screening of dried blood specimens from newborns.

  2003cited by this paper
• Nutritional cofactor treatment in mitochondrial disorders.

  2003cited by this paper
• The status of hematopoietic stem cell transplantation in lysosomal storage disease.

  2003cited by this paper
• Tetrahydrobiopterin as an alternative treatment for mild phenylketonuria.

  2002cited by this paper
• Steatohepatitis in children.

  2002cited by this paper
• The genetic consequences of our sweet tooth

  2002cited by this paper
• Penetrance of 845G→A (C282Y) HFE hereditary haemochromatosis mutation in the USA

  2002cited by this paper
• Glycogen storage disease type I: pathophysiology of liver adenomas

  2002cited by this paper
• Glycogen storage disease type I: diagnosis, management, clinical course and outcome. Results of the European study on glycogen storage disease type I (ESGSD I)

  2002cited by this paper
• Childhood porphyrias.

  2002influential reference
• Treatment of severe cholestasis in neonatal Dubin-Johnson syndrome with ursodeoxycholic acid

  2002cited by this paper
• Neue Screening-Richtlinien

  2002cited by this paper
• The deoxyguanosine kinase gene is mutated in individuals with depleted hepatocerebral mitochondrial DNA

  2001cited by this paper
• Applications of mass spectrometry in the study of inborn errors of metabolism

  2001cited by this paper
• Variable clinical presentation in lysosomal storage disorders

  2001cited by this paper
• The Metabolic and Molecular Bases of Inherited Disease

  2001cited by this paper
• Systematic approach to the diagnosis of lysosomal storage disorders.

  2001cited by this paper
• The hyperphenylalaninemia : phenylalanine hydroxylase deficiency

  2001cited by this paper
• Familial clustering of infantile cirrhosis in Northern Germany: A clue to the etiology of idiopathic copper toxicosis.

  1999cited by this paper
• Reye's syndrome in the United States from 1981 through 1997.

  1999cited by this paper
• Inborn errors of bile acid biosynthesis and transport. Novel forms of metabolic liver disease.

  1999cited by this paper
• A high index of suspicion: the key to an early diagnosis of Wilson's disease in childhood.

  1999cited by this paper
• Gilbert's syndrome is a contributory factor in prolonged unconjugated hyperbilirubinemia of the newborn.

  1999cited by this paper
• Correction of the UDP-glucuronosyltransferase gene defect in the gunn rat model of crigler-najjar syndrome type I with a chimeric oligonucleotide.

  1999cited by this paper
• A population-based study of the clinical expression of the hemochromatosis gene.

  1999cited by this paper
• Different clinical forms of hereditary tyrosinemia (type I) in patients with identical genotypes.

  1998cited by this paper
• Treatment of the Crigler-Najjar syndrome type I with hepatocyte transplantation.

  1998cited by this paper
• Mutations in the canilicular multispecific organic anion transporter (cMOAT) gene, a novel ABC transporter, in patients with hyperbilirubinemia II/Dubin-Johnson syndrome.

  1998cited by this paper
• Current therapy for Crigler‐Najjar syndrome type 1: Report of a world registry

  1996cited by this paper
• Elevated plasma chitotriosidase activity in various lysosomal storage disorders

  1995cited by this paper
• The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome.

  1995cited by this paper
• Screening for alpha1‐antitrypsin deficiency

  1994cited by this paper
• A lag in intracellular degradation of mutant alpha 1-antitrypsin correlates with the liver disease phenotype in homozygous PiZZ alpha 1-antitrypsin deficiency.

  1994cited by this paper
• Alpha1‐antitrypsin deficiency (PiZZ): features of liver involvement in childhood

  1994cited by this paper

• Grundlagen der Symptomtherapie

  2020cites this paper
• Associations between motion activity, ketosis risk and estrus behavior in dairy cattle.

  2019cites this paper